1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €62.14 (+97.27%). The median is €60.42 (+91.81%).
| Buy |
6 |
| Hold |
1 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | 100.00% |
| Net profit | -30.22M | 61.78% |
| EBITDA | -28.14M | 56.07% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €516.37M |
Number of shares | 15.8M |
52-week high/low | €37.68 - €13.75 |
| Dividends | No |
Beta | 1.95 |
P/E ratio | -6.87 |
PEG ratio | 0.39 |
P/B ratio | 3.93 |
P/S ratio | 0.00 |
Company profile
Neurogene Inc. entwickelt lebensverändernde genetische Medikamente für Patienten und deren Familien, die von neurologischen Krankheiten betroffen sind. Zu den Produktkandidaten des Unternehmens gehören NGN-401, eine AAV9-Gentherapie zur Behandlung des Rett-Syndroms, und NGN-101 zur Behandlung der neuronalen Ceroid-Lipofuszinose-Subtyp-5-Lattenkrankheit. Der Hauptsitz des Unternehmens befindet sich in New York, New York.
| Name | NEUROGENE INC |
| CEO | Rachel L. McMinn |
| Headquarters | New York City,
ny USA |
| Website | |
| Industry | Chemicals |
| IPO | 03/07/2014 |
| Employees | 131 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | NGNE |
Frankfurt | UU8.F |
Düsseldorf | UU8.DU |
Discover assets
Shareholders of NEUROGENE INC also invest in the following assets
